Clinical trials: Neoplastic Syndromes, Hereditary
Colorectal Adenomatous Polyp, Colorectal Carcinoma
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
The purpose of this phase I trial is to test the safety and cancer preventive effects of different doses of ONC201 in people with familial adenomatous polyposis (FAP) or a history of multiple polyps.
- Conditions
- Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
- Trial name
- NCT05630794
- Testing
- Biopsy Procedure, Biospecimen Collection, Colonoscopy
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
Neurofibromatosis Type 1, Precancerous Condition
Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Pirfenidone may slow the growth or prevent further development of plexiform neurofibromas.
- Trial name
- NCT00053937
- Testing
- pirfenidone
- Where
- 15 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Mental Health Issue
Determining the Effectiveness of Working Out Dads to Reduce Mental Health Difficulties in Fathers of Young Children
This is an individually randomised trial, where Working Out Dads (WOD) will be delivered as a group intervention. Participants will be randomised to one of two groups: either WOD or usual care.The trial aims to test the…
- Trial name
- WOD (NCT04813042)
- Testing
- Working Out Dads, Usual care
- Where
- Australia
- Volunteers
- 293 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
HNPCC
Uncertain Genetic Test Results for Lynch Syndrome
Background: Individuals have varying tolerances for receiving ambiguous information. However, not much is known about how ambiguous genetic testing information is received.
- Trial name
- NCT01646112
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Colorectal Cancer, Familial Adenomatous Polyposis
DNA Adductomics for Colorectal Cancer Investigation
This project seeks to identify DNA-adducts in colon tissue from different groups of patients with CRC scheduled for complete or partial colon resections. Other patients scheduled for resection of the colon serve as controls.
- Conditions
- Colorectal Cancer, Familial Adenomatous Polyposis, Hereditary Non-polyposis Colon Cancer, Lynch Syndrome
- Trial name
- adductomics (NCT04865601)
- Testing
- resectomy of the colon
- Where
- Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Tuberous Sclerosis Complex
Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
Study design is a Phase IIb prospective multi-center, randomized, placebo-controlled, double-blind clinical trial. The goal will be to enroll 80 infants with Tuberous Sclerosis Complex who are less than 6 months of age prior to…
- Trial name
- NCT02849457
- Testing
- Early Vigabatrin
- Where
- 13 sites in United States
- Volunteers
- 84 people
- Sponsor
- Martina Bebin
Glioma, Rhabdomyosarcoma
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
This study proposes to treat patients with the combination of erlotinib and temozolomide. Patients with relapsed, recurrent, refractory, or high risk malignancies whose tumors possess a non-synonymous mutation in EGFR, ERBB2, or…
- Conditions
- Glioma, Rhabdomyosarcoma, Osteosarcoma, Medulloblastoma
- Trial name
- NCT02689336
- Testing
- Erlotinib, Temozolomide
- Sponsor
- Washington University School of Medicine
Healthy, Men
Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
The long term objective is to develop a gel to be used as a male contraceptive.
- Conditions
- Healthy, Men, Male Contraception
- Trial name
- NCT03452111
- Testing
- Nestorone + Testosterone Combination Gel
- Where
- 17 sites in United States, Chile and 5 more
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Premier Research
Pediatric Solid Tumor, Osteosarcoma
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old…
- Conditions
- Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma
- Trial name
- NCT04897321
- Testing
- Fludarabine, Cyclophosphamide, MESNA
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- St. Jude Children's Research Hospital
Lynch Syndrome
Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants
The goal of this trial is to determine whether the Sage eConsent framework (presented using an electronic application) is non-inferior to traditional, paper-based, human-mediated consent-and therefore could be part of an…
- Trial name
- NCT04131062
- Testing
- Electronic Consent (iPad)
- Where
- United States
- Volunteers
- 703 people, healthy volunteers welcome
- Sponsor
- Geisinger Clinic
Wilms Tumor, Rhabdoid Tumor
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher…
- Conditions
- Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST
- Trial name
- NCT05985161
- Testing
- Selinexor
- Where
- 16 sites in United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neurofibromatosis Type 1
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Treatment Overview This phase II study will evaluate the activity of sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas that have the potential to cause significant morbidity.
- Trial name
- Protocol 102 (NCT00634270)
- Testing
- Sirolimus
- Where
- 9 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Alabama at Birmingham
Neurofibromatosis Type 1
How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem
The study will seek to determine whether there is a corresponding deficit in school performance for teenagers with NF1. Secondly, the study seeks to explore the issue of self-esteem in teenagers with NF1.
- Trial name
- NCT01626846
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- John Jay High School
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Neurofibromatosis, Neurofibromas
Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
This is a second Pilot Study to determine the efficacy of Gleevec® in neurofibromatosis (NF1) patients with plexiform neurofibromas using new response assessment modalities with the secondary goals of assessing Gleevec toxicity…
- Trial name
- 0908-09 (NCT01140360)
- Testing
- Gleevec
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Kent Robertson
Neurofibromatosis Type 1, Neurofibromatosis 1
Neurofibromatosis Type 1 Tumor Early Detection Study
The goal of this observational study is to determine if a liquid biopsy (i.e. blood test) is an effective clinical tool for monitoring the development of malignant peripheral nerve sheath tumor (MPNST) among adults (18 years and…
- Conditions
- Neurofibromatosis Type 1, Neurofibromatosis 1, Plexiform Neurofibroma, Plexiform Neurofibromas
- Trial name
- NF1-TED (NCT06515860)
- Testing
- Liquid biopsy for MPNST development
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- David Miller
Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
Phase I trial to study the effectiveness of SB-715992 in treating patients who have acute leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes.
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00098826
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Pediatric Oncology
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Dose escalation phase of the study : To define the safety profile, maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of regorafenib administered orally as a single agent in a 3-weeks-on/1- week-off schedule in…
- Trial name
- NCT02085148
- Testing
- Regorafenib (BAY73-4506), Vincristine (Cellcristin®), Irinotecan (Irinotecan Cell pharm®)
- Where
- 12 sites in France, Italy and 2 more
- Volunteers
- 62 people
- Sponsor
- Bayer
Familial Adenomatous Polyposis
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
This is a multicenter, two-part trial in participants with FAP.
- Trial name
- TUPELO (NCT05552755)
- Testing
- REC-4881
- Where
- 17 sites in United States
- Volunteers
- 67 people
- Sponsor
- Recursion Pharmaceuticals Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.